Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions

Cardiovasc Diabetol. 2020 Mar 10;19(1):29. doi: 10.1186/s12933-020-01004-9.

Abstract

The study regarding load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction is very interesting. But there are a few things we need to pay attention to.

Keywords: Empagliflozin; Heart failure with reduced ejection fraction; Sodium-glucose linked cotransporter-2 inhibitor.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Animals
  • Benzhydryl Compounds
  • Glucosides
  • Heart Failure*
  • Sodium-Glucose Transporter 2 Inhibitors*
  • Stroke Volume

Substances

  • Benzhydryl Compounds
  • Glucosides
  • Sodium-Glucose Transporter 2 Inhibitors
  • empagliflozin